Subjects receive Weekly Paclitaxel, intravenously, d1, d8, d15, d22, q4w, Dosage form: injectable, Strength: 80 mg/m2

Subjects receive Placebo, intravenously, d1, d15, q4w, Dosage form: injectable, Strength: 1.5 mg/kg

Subjects receive Topotecan, intravenously, d1, d8, d15, q4w, Dosage form: injectable, Strength: 4mg/m2

Subjects receive doxorubicin liposome, intravenously, d1, , q4w, Dosage form: injectable, Strength: 40mg/m2

Proportion of subjects who have a complete or partial response relative to baseline as assessed by investigator according to RECIST 1.1 criteria

Proportion of subjects who have a complete or partial response, or stable disease relative to baseline as assessed by investigator according to RECIST 1.1 criteria

Measured from the date of partial or complete response to therapy until the cancer progresses based on RECIST v1.1 criteria.

Proportion of subjects who have a complete or partial response relative to baseline as assessed by BIRC according to RECIST 1.1 criteria

Proportion of subjects who have a complete or partial response, or stable disease relative to baseline as assessed by BIRC according to RECIST 1.1 criteria

Measured from the date of partial or complete response to therapy until the cancer progresses based on RECIST v1.1 criteria.

Frequency and severity of Adverse Events or Serious Adverse Events as defined by CTCAE version 5.0

use European Organisation for Research and Treatment of Cance（EORTC）- QLQ-C30 questionnaire

use EORTC-QLQ-OV28 questionnaire

Serum drug concentrations of BD0801 will be calculated.